Literature DB >> 14593549

Diagnostic criteria in polycystic ovary syndrome.

Richard S Legro1.   

Abstract

Part of the difficulty in understanding polycystic ovary syndrome (PCOS) and interpreting the dense literature surrounding it is that there is no universally accepted clinical definition. The varying definitions influence the incidence, prevalence of sequelae, and response to treatment. PCOS is clearly heterogeneous and its etiology is still speculative. Over the years it has evolved from a "disease" to a "syndrome," the latter which includes a variety of potential signs and symptoms, including oligo-ovulation, biochemical or clinical hyperandrogenism, polycystic ovaries, and insulin resistance. There is no single diagnostic criterion that can be recommended for diagnosis of PCOS. While hyperandrogenemia, specifically elevated bioavailable testosterone, is intellectually appealing, the evidence in terms of long-term sequelae identified by such a test is still weak. The recognition of oligo-ovulation primarily relies on patient history. Currently both consensus and the preliminary evidence-based trials support a combination of hyperandrogenemia and oligo-ovulation, in the absence of known causes, as diagnostic criteria, but there are also strong proponents of using ovarian morphology to identify and diagnose the syndrome. There are no simple clinically validated biochemical tests of insulin resistance. Further identification of specific causes, and elimination of the multiple phenocopies that make up PCOS, will ease its diagnosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14593549     DOI: 10.1055/s-2003-43304

Source DB:  PubMed          Journal:  Semin Reprod Med        ISSN: 1526-4564            Impact factor:   1.303


  7 in total

1.  Acute uterine bleeding unrelated to pregnancy: a Southern California Permanente Medical Group practice guideline.

Authors:  Malcolm G Munro
Journal:  Perm J       Date:  2013

2.  A population-based study of maternal and perinatal outcomes associated with assisted reproductive technology in Massachusetts.

Authors:  Laura A Schieve; Bruce Cohen; Angela Nannini; Cynthia Ferre; Meredith A Reynolds; Zi Zhang; Gary Jeng; Maurizio Macaluso; Victoria C Wright
Journal:  Matern Child Health J       Date:  2007-03-08

3.  Polycystic ovarian syndrome is accompanied by repression of gene signatures associated with biosynthesis and metabolism of steroids, cholesterol and lipids.

Authors:  Dessie Salilew-Wondim; Qi Wang; Dawit Tesfaye; Karl Schellander; Michael Hoelker; Md Munir Hossain; Benjamin K Tsang
Journal:  J Ovarian Res       Date:  2015-04-13       Impact factor: 4.234

4.  Polycystic ovary syndrome in Salvador, Brazil: a prevalence study in primary healthcare.

Authors:  Ligia Gabrielli; Estela M I Aquino
Journal:  Reprod Biol Endocrinol       Date:  2012-11-22       Impact factor: 5.211

5.  Integrated analyses for genetic markers of polycystic ovary syndrome with 9 case-control studies of gene expression profiles.

Authors:  Chenqi Lu; Xiaoqin Liu; Lin Wang; Ning Jiang; Jun Yu; Xiaobo Zhao; Hairong Hu; Saihua Zheng; Xuelian Li; Guiying Wang
Journal:  Oncotarget       Date:  2017-01-10

6.  Hirsutism in Saudi females of reproductive age: a hospital-based study.

Authors:  Atallah D Al-Ruhaily; Usman H Malabu; Riad A Sulimani
Journal:  Ann Saudi Med       Date:  2008 Jan-Feb       Impact factor: 1.526

7.  Firing patterns of gonadotropin-releasing hormone neurons are sculpted by their biologic state.

Authors:  Jonathon Penix; R Anthony DeFazio; Eden A Dulka; Santiago Schnell; Suzanne M Moenter
Journal:  R Soc Open Sci       Date:  2020-08-12       Impact factor: 2.963

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.